You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

Type 2 Inflammation

ADVENT at EAACI 2025

Join Profs. Brian Lipworth, Zuzana Diamant and Philippe Gevaert at an sponsored symposium about the latest strategies for the management of co-existing type 2 asthma and severe and/or uncontrolled CRSwNP.

Remind me

13 - 16Jun2025

Begins in

31days

13hours

Symposium Details

June 13

At the Intersection of Type 2 Airways: Navigating the Challenges of Comorbid Asthma & CRSwNP

Join Profs. Brian Lipworth, Zuzana Diamant, and Philippe Gevaert in Glasgow, Scotland on June 13th from 12:00-13:00 for a promotional symposium exploring the complexities of comorbid asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Gain valuable insights into diagnosis, treatment strategies, and emerging therapies for patients with these overlapping Type 2 airway diseases. Products will be discussed. Adverse Event reporting and prescribing information will be available.

Agenda

Welcome & Introductions

Brian Lipworth

Compounded Burden of Co-existing Type 2 Airway Diseases

Brian Lipworth

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

Zuzana Diamant

CRSwNP at Center Stage: Impact of Biologics in Patients with Comorbid Type 2 Asthma

Philippe Gevaert

Panel Discussion & Audience Q&A

All Faculty

Tags

type 2 inflammation upper airway coexisting diseases disease control

MAT-GLB-2502398 - 1.0 - 05/2025

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: PolandChange country/region